The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

Tech in AsiaAsia

AstraZeneca strikes $1.5b AI drug discovery deal with Insitro

October 16

AstraZeneca will pay insitro US$40 million upfront.

Models & releases Funding & deals

Read at Tech in Asia ↗

One letter a week, starting soon.

Latest

AstraZeneca strikes $1.5b AI drug discovery deal with Insitro

Related

ValleyRamp raises $1.85B as it expands beyond finance software SiliconANGLE

SiliconJapan Offers GlobalFoundries $21B for U.S. Fab Expansion EE Times

Voices[AINews] Modal’s $1B ARR, $16B Series D makes it NYC’s newest AI Infra Decacorn, 3x usage and 3x valuation in 5 months, 15x in 1 yr Latent Space

AsiaChina chip exports jump 136% to US$45b as AI frenzy jacks up prices SCMP Tech

ToolsModal crosses $1B in Annualized Run Rate and raises $750M Series D Modal

Voices[AINews] TypeSafe/Jev at >$100M ARR, $7.5B valuation 3 weeks after launch Latent Space